Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients.
Here we report a unique situation in which an early and synchronized Epstein-Barr virus (EBV) reactivation was induced by a 6-day course of treatment with a humanized CD3-specific monoclonal antibody in patients with recent onset of type 1 diabetes. The virologic and immunologic analysis demonstrate...
| Автори: | , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Journal article |
| Мова: | English |
| Опубліковано: |
2010
|
| _version_ | 1826263233121484800 |
|---|---|
| author | Keymeulen, B Candon, S Fafi-Kremer, S Ziegler, A Leruez-Ville, M Mathieu, C Vandemeulebroucke, E Walter, M Crenier, L Thervet, E Legendre, C Pierard, D Hale, G Waldmann, H Bach, J Seigneurin, J Pipeleers, D Chatenoud, L |
| author_facet | Keymeulen, B Candon, S Fafi-Kremer, S Ziegler, A Leruez-Ville, M Mathieu, C Vandemeulebroucke, E Walter, M Crenier, L Thervet, E Legendre, C Pierard, D Hale, G Waldmann, H Bach, J Seigneurin, J Pipeleers, D Chatenoud, L |
| author_sort | Keymeulen, B |
| collection | OXFORD |
| description | Here we report a unique situation in which an early and synchronized Epstein-Barr virus (EBV) reactivation was induced by a 6-day course of treatment with a humanized CD3-specific monoclonal antibody in patients with recent onset of type 1 diabetes. The virologic and immunologic analysis demonstrated that this reactivation was transient, self-limited, and isolated, associated with the rapid advent of an EBV-specific T-cell response. The anti-CD3 antibody administration induced short-lasting immunosuppression and minor yet clear-cut signs of T-cell activation that preceded viral reactivation. Early posttransplant monitoring of renal and islet allograft recipients showed that no comparable phenomenon was observed after the administration of full-dose immunosuppressive therapy. This EBV reactivation remains of no apparent clinical concern over the long term and should not preclude further development of therapeutic anti-CD3 antibodies. This phenomenon may also direct new research avenues to understand the still ill-defined nature of stimuli triggering EBV reactivation in vivo. |
| first_indexed | 2024-03-06T19:48:28Z |
| format | Journal article |
| id | oxford-uuid:2326342b-d94f-4bac-a13d-b0eba3992985 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:48:28Z |
| publishDate | 2010 |
| record_format | dspace |
| spelling | oxford-uuid:2326342b-d94f-4bac-a13d-b0eba39929852022-03-26T11:42:47ZTransient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2326342b-d94f-4bac-a13d-b0eba3992985EnglishSymplectic Elements at Oxford2010Keymeulen, BCandon, SFafi-Kremer, SZiegler, ALeruez-Ville, MMathieu, CVandemeulebroucke, EWalter, MCrenier, LThervet, ELegendre, CPierard, DHale, GWaldmann, HBach, JSeigneurin, JPipeleers, DChatenoud, LHere we report a unique situation in which an early and synchronized Epstein-Barr virus (EBV) reactivation was induced by a 6-day course of treatment with a humanized CD3-specific monoclonal antibody in patients with recent onset of type 1 diabetes. The virologic and immunologic analysis demonstrated that this reactivation was transient, self-limited, and isolated, associated with the rapid advent of an EBV-specific T-cell response. The anti-CD3 antibody administration induced short-lasting immunosuppression and minor yet clear-cut signs of T-cell activation that preceded viral reactivation. Early posttransplant monitoring of renal and islet allograft recipients showed that no comparable phenomenon was observed after the administration of full-dose immunosuppressive therapy. This EBV reactivation remains of no apparent clinical concern over the long term and should not preclude further development of therapeutic anti-CD3 antibodies. This phenomenon may also direct new research avenues to understand the still ill-defined nature of stimuli triggering EBV reactivation in vivo. |
| spellingShingle | Keymeulen, B Candon, S Fafi-Kremer, S Ziegler, A Leruez-Ville, M Mathieu, C Vandemeulebroucke, E Walter, M Crenier, L Thervet, E Legendre, C Pierard, D Hale, G Waldmann, H Bach, J Seigneurin, J Pipeleers, D Chatenoud, L Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. |
| title | Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. |
| title_full | Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. |
| title_fullStr | Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. |
| title_full_unstemmed | Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. |
| title_short | Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. |
| title_sort | transient epstein barr virus reactivation in cd3 monoclonal antibody treated patients |
| work_keys_str_mv | AT keymeulenb transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT candons transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT fafikremers transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT zieglera transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT leruezvillem transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT mathieuc transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT vandemeulebrouckee transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT walterm transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT crenierl transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT thervete transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT legendrec transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT pierardd transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT haleg transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT waldmannh transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT bachj transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT seigneurinj transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT pipeleersd transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients AT chatenoudl transientepsteinbarrvirusreactivationincd3monoclonalantibodytreatedpatients |